I have read the Research and Markets' Privacy Policy and consent to the processing of my personal data.*

RECENTLY VIEWED PRODUCTS

TESTIMONIALS

The Service I received from the Orders and Customer Service Team was very professional. Their responses were very quick and actioned on immediately.

Mr Gueorgui TzvetanovSenior ManagerERGO Austria International AG

The Research and Markets’ customer support team provided me with timely and immediate responses and delivered exactly the information that I was looking for – great job. Thank you very much. I would recommend them to anybody who is looking for market research data.

Great customer service and super responsive. I was having issues with my payment method but Claire in customer service was super responsive to help several times until the issue was entirely resolved. Great job

Mr Detlef RethagePresidentNitto Avecia Inc

The reports ordered are of good quality and are relevant to our business needs.

Mr Etienne AdriansenSenior Director Business EvaluationLEO Pharma

Thank you for all of your help! I think your service is excellent. It is an easy platform to order interesting reports.

Mr Tomi AmberlaConsultantPöyry Management Consulting

The team at Research and Markets are first rate. Their market intelligence is relevant and accurate and the customer service fast, responsive and dependable. I always benefit from knowledge gained from their comprehensive studies and will continue to utilize their services.

Ms Liz DickinsonCEOPhysical Enterprises Inc

I have bought reports from other sources but the report that I bought from Research and Markets was the most detailed of the lot. Their customer service was excellent and I was able to get the report without any fuss.

Mr Naveed KamalAsst Manager: Business DevelopmentRangs Group Ltd

Celebrating 15
years in business
by partnering
with UNICEF for education

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides comprehensive insights across PD-1 and PD-L1 Inhibitors including detailed Marketed product profiles. The report has information on detailed pipeline portfolio including Phase III, Phase II, Phase I, Pre-Clinical and Discovery Products. With more than 50 products in various stages of development, the pipeline seems encouraging which has made PD-1 and PD-L1 the most talked about Immuno-oncology target.

There are 50+products in pipeline and 5 products have been marketed so far. The focus is majorly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells to restore latent anti-tumor immunity.

Key Coverage and Benefits:

1. In-depth analysis of the 50+ pipeline assets.2. Pipeline landscape provides a deep dive into clinical, pre-clinical and discovery molecules.3. Extensive coverage of Technology implemented by companies in this space.4. Licensing and Deals related to PD-1 and PD-L1 inhibitors are also covered.5. Insights on marketed products including detailed marketed product profiles. Also includes Historical and Five years forecasted sales for Marketed products (Opdivo, Keytruda, Tecentriq, Bavencio and Imfinzi).6. Extensive coverage of ASCO 2017 updates and related insights.7. Therapeutic assessment by molecule type, route of administration, monotherapy and combination products.8. Detailed information on inactive projects in the pipeline for PD-1 & PD-L1 Inhibitors.9. Information to identify emerging players with potentially lucrative products.

Note: Please allow up to 24 hours for delivery after payment has been made.

Note: This product will be delivered within 24 hours from the time of purchase.